Overexpression of HIPK2 removes the transrepression of proapoptotic genes mediated by the CtBP1-p300-FOXO3a complex and increases the chemosensitivity in osteosarcoma cells

Ning Duan, Wentao Zhang, Zhong Li, Liang Sun, Tao Song, Zirui Yu, Xun Chen, Wei MaJournal of Cancer 2021 · DOI

TL;DR

This study identifies Homeodomain-interacting protein kinase 2 (HIPK2) as a crucial regulator of cancer cell apoptosis and chemosensitivity in osteosarcoma. By phosphorylating and promoting the degradation of the transcriptional repressor CtBP1, HIPK2 disassembles a complex that normally suppresses pro-apoptotic genes, thereby sensitizing cancer cells to chemotherapy.

What Problem Does This Paper Address?

Cancer cells often develop resistance to chemotherapy by evading apoptosis, the programmed cell death that many cancer drugs aim to induce. This resistance can stem from the dysregulation of genes that promote apoptosis. The paper focuses on osteosarcoma, a bone cancer where chemoresistance is a significant challenge. Previous research identified a complex involving CtBP1, p300, and FOXO3a that actively suppresses the expression of key pro-apoptotic genes like BAX and BIM. However, the upstream signals that control the activity of this repressive complex were unclear, leaving a gap in understanding how to therapeutically target this pathway to restore chemosensitivity.

Methods

The researchers employed a multi-pronged approach:

  • Gene Expression Analysis: RT-qPCR was used to quantify mRNA levels of HIPK2, CtBP1, CtBP2, and several pro-apoptotic genes in osteosarcoma cell lines and patient biopsies.
  • Protein Analysis: Western blotting was used to assess protein levels of HIPK2, CtBP1, phosphorylated CtBP1 (pCtBP1), CtBP2, and various apoptotic markers (caspases, pro-apoptotic proteins).
  • Cell Culture and Transfection: Standard cell culture techniques were used. Lentiviral shRNAs were employed for gene knockdown (CtBP1, HIPK2), and plasmids were used for gene overexpression (HIPK2).
  • Immunoprecipitation: This technique was used to confirm the physical interaction between CtBP1, p300, and FOXO3a.
  • Reporter Assays: Luciferase reporter assays were utilized to investigate the transcriptional regulation of pro-apoptotic genes by the CtBP1-p300-FOXO3a complex, using wild-type and mutated promoter constructs.
  • In vitro Oncogenic Phenotype Assays: MTT assays (cell viability), colony formation assays, and cell invasion assays were performed to assess the impact of HIPK2 manipulation on cancer cell behavior.
  • In vivo Tumor Xenograft Model: Osteosarcoma cells with altered HIPK2 expression were implanted into mice to evaluate tumor growth and response to chemotherapy.
  • Microarray Analysis: This was used to identify a broader set of differentially expressed genes in HIPK2-overexpressing cells.

Datasets

The study utilized human osteosarcoma cell lines (DAN, MG63, HOS, T1-73, 143B, Saos2, U2OS) and a human osteoblast cell line (hFOB1.19) as controls. Additionally, paired osteosarcoma and adjacent non-cancerous tissue samples from 20 patients were used for gene expression analysis. No new benchmark datasets were introduced.

Key Insights and Ideas

  • HIPK2 as a "Gatekeeper" of Apoptosis: The study reveals HIPK2 as a critical upstream regulator that controls the activity of the CtBP1-p300-FOXO3a complex. Its downregulation in osteosarcoma is a key event enabling cancer cell survival.
  • Phosphorylation-Driven Degradation: HIPK2's primary mechanism appears to be the phosphorylation of CtBP1, marking it for proteasomal degradation. This is a crucial post-translational modification that directly impacts CtBP1's abundance and function.
  • Restoring the Balance: By restoring HIPK2 levels, the researchers could reverse the effects of CtBP1 overexpression, leading to the re-expression of pro-apoptotic genes and increased sensitivity to chemotherapy.
  • Therapeutic Potential: The findings strongly suggest that HIPK2 could be a valuable therapeutic target for overcoming chemoresistance in osteosarcoma.

Key Results

  • Inverse Expression: HIPK2 mRNA and protein levels were significantly downregulated in osteosarcoma cells and biopsies, while CtBP1 levels were inversely upregulated. Phosphorylated CtBP1 (pCtBP1) levels were also reduced in cancer tissues.
  • HIPK2 Overexpression Effects: Overexpression of HIPK2 in osteosarcoma cells led to:
  • Decreased CtBP1 protein levels and increased pCtBP1 levels.
  • Increased expression of pro-apoptotic genes (BIM, BIK, BAX, NOXA).
  • Inhibition of cell proliferation, colony formation, and invasion in vitro.
  • Significant suppression of tumor growth in vivo.
  • Enhanced sensitivity to chemotherapeutic drugs (CDDP and MTX).
  • Mechanism Confirmation: Immunoprecipitation confirmed the formation of the CtBP1-p300-FOXO3a complex. Luciferase assays demonstrated that FOXO3a binding sites on pro-apoptotic gene promoters were essential for this complex's repressive activity.
  • Apoptosis Induction: HIPK2 overexpression induced the activation of key caspases (CASP3, CASP7, CASP9), indicating the activation of apoptotic pathways.

Limitations and Future Work

  • Transcriptional Regulation of CtBP1: While HIPK2's role in CtBP1 phosphorylation and degradation is elucidated, the paper notes that the transcriptional regulation of CtBP1 in osteosarcoma remains unclear.
  • EMT and Metastasis: The study briefly mentions that HIPK2 overexpression reduced CDH1 (an EMT marker) and TGFB1 expression, suggesting potential effects on EMT and metastasis. However, the paper acknowledges that more research is needed to fully understand HIPK2's influence on these processes.
  • Broader Therapeutic Applications: While the focus is on osteosarcoma, the findings on HIPK2's role in apoptosis and chemosensitivity could potentially be explored in other cancer types where CtBP1 is implicated. Further investigation into the precise mechanisms by which HIPK2 influences other cellular processes beyond apoptosis is also warranted.

Summary updated

Abstract

Decreased expression of proapoptotic genes can lead to the chemoresistenance in cancer therapy. Carboxyl-terminal binding protein 1 (CtBP1), a transcriptional corepressor with multiple oncogenic effects, has been previously identified to suppress the expression of two proapoptotic genes [<i>BAX</i> (BCL2 associated X) and <i>BIM</i> (Bcl-2 interacting mediator of cell death)] by assembling a complex with the Forkhead box O3 (FOXO3a) transcription factor and the p300 histone acetyltransferase. However, the upstream regulatory signaling of the CtBP1-p300-FOXO3a complex is obscure, and the effects of changing this signaling on chemosensitivity in osteosarcoma are unknown. Herein, we discovered that the downregulation of <i>HIPK2</i> (Homeodomain-interacting protein kinase 2) was essential for the function of the CtBP1-p300-FOXO3a complex. Downregulation of <i>HIPK2</i> prevented the phosphorylation and subsequent degradation of CtBP1, thereby allowing the assembly of the CtBP1-p300-FOXO3a complex and suppression of the expression of proapoptotic genes, such as <i>BAX</i>, <i>BIM</i>, <i>BIK</i> (Bcl-2 interacting killer) and <i>NOXA</i>/<i>PMAIP1</i> (Phorbol-12-myristate-13-acetate-induced protein 1). Overexpression of <i>HIPK2</i> promoted the phosphorylation of CtBP1 and the degradation of CtBP1 by proteasomes, thereby preventing the formation of the CtBP1-p300-FOXO3a complex. The abolition of CtBP1 transrepression increased the expression of proapoptotic genes to induce apoptosis and increase chemosensitivity in osteosarcoma cells. Taken together, our <i>in vitro</i> and <i>in vivo</i> results revealed that overexpression of <i>HIPK2</i> could remove the CtBP1-mediated transrepression of proapoptotic genes, indicating a new therapeutic option for the treatment of osteosarcoma.
BibTeX
@article{duan2021overexpression,
  author = {Ning Duan and Wentao Zhang and Zhong Li and Liang Sun and Tao Song and Zirui Yu and Xun Chen and Wei Ma},
  title = {{Overexpression of <i>HIPK2</i> removes the transrepression of proapoptotic genes mediated by the CtBP1-p300-FOXO3a complex and increases the chemosensitivity in osteosarcoma cells}},
  journal = {Journal of Cancer},
  year = {2021},
  doi = {10.7150/jca.52115},
}
Figure